Inventiva Eyes Q4 2026 Phase III MASH Data as Lanifibranor Nears Key Test Inventiva NASDAQ: IVA sai...
Topics
Inventiva Eyes Q4 2026 Phase III MASH Data as Lanifibranor Nears Key Test Inventiva NASDAQ: IVA said it expects to report top-line results in the fourth quarter of 2026 from its fully enrolled Phase III NATiV3 trial of lanifibranor in patients with metabolic dysfunction-associated steatohepatitis, or MASH.
Related QATS news
- Better High-Yield Dividend Stock: Pfizer or Novo Nordisk? Novo Nordisk is a leading GLP-1 company, ...
- Kodiak AI Targets Year-End Driverless Dallas-Houston Trucking Launch With IKEA Kodiak AI NASDAQ: KD...
- Forget the S&P 500: SCHD Is Beating It by Nearly 10 Points in 2026 and Its Dividend Just Grew SCHD ...
- Is Netflix (NFLX) Stock a Buy? Netflix is huge and still growing. But its valuation isn't dirt chea...